Mid-term hemodynamic performance of INSPIRIS RESILIA aortic bioprosthesis for severe aortic stenosis

We investigated mid-term outcomes after aortic valve replacement (AVR) with INSPIRIS RESILIA (IR) aortic bioprosthesis for severe aortic stenosis (AS). A total of 60 patients with a mean age of 73.2±6.2 years underwent AVR with IR bioprosthesis for severe AS. We prospectively followed up on 59 survivors and collected transthoracic echocardiographic data at 3-6 months, and annually thereafter. The mean follow-up period was 3.0±1.5 years, with a 100% follow-up rate. The preoperative mean pressure gradient (PG) and the effective orifice area were 52.5±18.2 mmHg, and 0.73±0.23 cm2, respectively, which improved to 10.3±3.5 mmHg (P<0.001), and 1.85±0.48 cm2 (P<0.001) at discharge. The mean PG at 5 years was 10.2±2.7 mmHg, which was similar to one at discharge (P=0.307). Left ventricular mass index decreased from 119.6±33.1 g/m2 before AVR to 104.0±32.5 g/m2 (P<0.001) at discharge, and further decreased to 78.5±22.2 g/m2 at 5 years compared with postoperative one (P=0.011). Survival rate at 5 years was 97.4±2.6%. Freedom from valve-related events at 5 years was 91.4±5.5%. Incidental cerebral infarction (n=2) and heart failure (n=1) were noted. IR bioprosthesis demonstrated a stable hemodynamic performance and few valve-related events. J. Med. Invest. 72 : 390-395, August, 2025.